Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,823 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,089 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05809336 | Gut Microbial Metabolites Inosine Combined With PD-1/PD-L1 Inhibitor for Patients With Malignant Advanced Solid Tumors | completed | Phase 2 / Phase 3 | 172 | Beijing Friendship HospitalOTHER | 1 | Apr 12, 2023 | clinicaltrials |
| NCT05805956 | IMM2902 in Patients With Advanced Solid Tumors Expressing HER2 | unknown | Phase 1 / Phase 2 | 105 | ImmuneOnco Biopharmaceuticals (Shanghai) Inc.OTHER | 1 | Apr 10, 2023 | clinicaltrials |
| NCT02754141 | An Investigational Immuno-therapy Study of Experimental Medication BMS-986179 Given Alone and in Combination With Nivolumab | completed | Phase 1 / Phase 2 | 235 | Bristol-Myers SquibbINDUSTRY | 7 | Apr 5, 2023 | clinicaltrials |
| NCT05204862 | Phase 1/2 Study of TU2218 Alone and in Combination With Checkpoint Inhibitors in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 240 | TiumBio Co., Ltd.INDUSTRY | 2 | Apr 3, 2023 | clinicaltrials |
| NCT05785728 | A Study of DB-1202 Monotherapy in Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 150 | DualityBio Inc.INDUSTRY | 1 | Mar 31, 2023 | clinicaltrials |
| NCT05790447 | Thymalfasin-based PRaG Mode for Advanced Refractory Solid Tumors | unknown | Phase 2 | 60 | Second Affiliated Hospital of Soochow UniversityOTHER | 1 | Mar 30, 2023 | clinicaltrials |
| NCT04522284 | PRECISE CURATE.AI Pilot Clinical Trial | unknown | Phase 1 / Phase 2 | 20 | National University Hospital, SingaporeOTHER | 1 | Mar 29, 2023 | clinicaltrials |
| NCT03616834 | Tomivosertib (eFT-508) in Combination With PD-1/PD-L1 Inhibitor Therapy | completed | Phase 2 | 39 | Effector TherapeuticsINDUSTRY | 1 | Mar 22, 2023 | clinicaltrials |
| NCT05010525 | A Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of ATG 016 Monotherapy in Patients With Advanced Solid Tumors(REACH) | terminated | Phase 1 / Phase 2 | 8 | Shanghai Antengene Corporation LimitedINDUSTRY | 1 | Mar 17, 2023 | clinicaltrials |
| NCT05434299 | A Study of TFX05-01 in Patients With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 36 | Zhejiang Yangli Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Mar 16, 2023 | clinicaltrials |
| NCT04565275 | A Study of ICP-192 in Patients With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 45 | Beijing InnoCare Pharma Tech Co., Ltd.INDUSTRY | 2 | Mar 14, 2023 | clinicaltrials |
| NCT05733000 | CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors | recruiting | Phase 2 | 94 | Northwestern UniversityOTHER | 1 | Mar 10, 2023 | clinicaltrials |
| NCT05008445 | Study of LM-102 in Patients With Advance Solid Tumors | terminated | Phase 1 / Phase 2 | 11 | LaNova Medicines Development Co., Ltd.INDUSTRY | 1 | Mar 9, 2023 | clinicaltrials |
| NCT02598960 | An Investigational Immuno-therapy Study of Experimental Medication BMS-986156, Given by Itself or in Combination With Nivolumab in Patients With Solid Cancers or Cancers That Have Spread. | completed | Phase 1 / Phase 2 | 295 | Bristol-Myers SquibbINDUSTRY | 10 | Mar 6, 2023 | clinicaltrials |
| NCT03475953 | A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors(REGOMUNE) | unknown | Phase 1 / Phase 2 | 747 | Institut BergoniéOTHER | 1 | Mar 3, 2023 | clinicaltrials |
| NCT05175235 | Nivolumab and Pembrolizumab Dose Optimisation in Solid Tumours With CURATE.AI Platform and Sequential ctDNA Measurements | unknown | Phase 1 / Phase 2 | 10 | National University Hospital, SingaporeOTHER | 1 | Mar 3, 2023 | clinicaltrials |
| NCT02454972 | Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors | completed | Phase 2 | 345 | PharmaMarINDUSTRY | 9 | Mar 2, 2023 | clinicaltrials |
| NCT04169672 | Study of Surufatinib Single Agent or Surufatinib Combined With Toripalimab in Patients With Advanced Solid Tumors | completed | Phase 2 | 248 | Hutchison Medipharma LimitedINDUSTRY | 1 | Mar 2, 2023 | clinicaltrials |
| NCT05748938 | A Study of RD14-01 in Patients With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 12 | 920th Hospital of Joint Logistics Support Force of People's Liberation Army of ChinaOTHER | 1 | Mar 1, 2023 | clinicaltrials |
| NCT05419817 | Pembrolizumab With Sitravatinib in Recurrent Endometrial Cancer and Other Solid Tumors With Deficient Mismatch Repair System | withdrawn | Phase 2 | 0 | Haider MahdiOTHER | 0 | Feb 27, 2023 | clinicaltrials |
| NCT05222165 | Study With Infigratinib in Subjects With Advanced Solid and CNS Tumors or Recurrent or Progressive Low-Grade Glioma With Selected FGFR1-3 Alterations(NEWEL) | withdrawn | Phase 1 / Phase 2 | 0 | Helsinn Healthcare SAINDUSTRY | 3 | Feb 23, 2023 | clinicaltrials |
| NCT05740215 | Efficacy and Safety Study of F520 Combined With Lenvatinib in the Treatment of Patients With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 158 | Shandong New Time Pharmaceutical Co., LTDINDUSTRY | 1 | Feb 22, 2023 | clinicaltrials |
| NCT04592484 | A First-in-Human Study of CDK-002 (exoSTING) in Subjects With Advanced/Metastatic, Recurrent, Injectable Solid Tumors | completed | Phase 1 / Phase 2 | 27 | Codiak BioSciencesINDUSTRY | 2 | Feb 8, 2023 | clinicaltrials |
| NCT04518137 | A Study of Evaluating the Safety and Efficacy of ATG-008 for Advanced Solid Tumors (BUNCH) | terminated | Phase 2 | 5 | Shanghai Antengene Corporation LimitedINDUSTRY | 1 | Jan 31, 2023 | clinicaltrials |
| NCT05642949 | Study of MHB036C in Participants With Advanced or Metastatic Solid Tumors | unknown | Phase 1 / Phase 2 | 400 | Minghui Pharmaceutical Pty LtdINDUSTRY | 1 | Jan 9, 2023 | clinicaltrials |
| NCT02393248 | Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101) | terminated | Phase 1 / Phase 2 | 201 | Incyte CorporationINDUSTRY | 2 | Jan 6, 2023 | clinicaltrials |
| NCT05372120 | A Clinical Trial of ICP-192 in Treated Patients With Advanced Solid Tumors With FGF/FGFR Gene Alterations | unknown | Phase 2 | 200 | Beijing InnoCare Pharma Tech Co., Ltd.INDUSTRY | 1 | Jan 4, 2023 | clinicaltrials |
| NCT04800627 | Pevonedistat and Pembrolizumab for the Treatment of dMMR/MSI-H Metastatic or Locally Advanced Unresectable Solid Tumor | terminated | Phase 1 / Phase 2 | 2 | M.D. Anderson Cancer CenterOTHER | 1 | Dec 27, 2022 | clinicaltrials |
| NCT05214976 | A Trial of Camrelizumab for Injection in Combination With Famitinib Malate Capsule and Paclitaxel For Injection(Albumin Bound) in Advanced Solid Tumors of Patients | unknown | Phase 2 | 64 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Dec 22, 2022 | clinicaltrials |
| NCT04042116 | A Study to Evaluate Lucitanib in Combination With Nivolumab in Patients With a Solid Tumor | suspended | Phase 1 / Phase 2 | 227 | Clovis Oncology, Inc.INDUSTRY | 6 | Dec 20, 2022 | clinicaltrials |
| NCT04851834 | NTX-301 Monotherapy in Advanced Solid Tumours and in Combination With Platinum-based Chemotherapy in Advanced Ovarian & Bladder Cancer and in Combination With Temozolomide in High-grade Glioma | terminated | Phase 1 / Phase 2 | 12 | Xennials Therapeutics Australia Pty LtdINDUSTRY | 1 | Dec 20, 2022 | clinicaltrials |
| NCT04372706 | RTX-240 Monotherapy and in Combination With Pembrolizumab | terminated | Phase 1 / Phase 2 | 69 | Rubius TherapeuticsINDUSTRY | 1 | Dec 13, 2022 | clinicaltrials |
| NCT04614740 | The Phase I/Phase II Clinical Study of VC004 in Patients With Localized Advanced/Metastatic Solid Tumors | unknown | Phase 1 / Phase 2 | 115 | Jiangsu vcare pharmaceutical technology co., LTDINDUSTRY | 1 | Dec 13, 2022 | clinicaltrials |
| NCT04481009 | A Study to Evaluate YH003 in Combination With Toripalimab (Anti-PD-1 mAb) in Subjects With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 26 | Eucure (Beijing) Biopharma Co., LtdINDUSTRY | 1 | Dec 12, 2022 | clinicaltrials |
| NCT05645315 | Clinical Trial of TQB2618 Injection Combined With TQB2450 Injection in Patients With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 127 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Dec 9, 2022 | clinicaltrials |
| NCT02762981 | Study to Evaluate Relacorilant (CORT125134) in Combination With Nab-paclitaxel in Participants With Solid Tumors | completed | Phase 1 / Phase 2 | 85 | Corcept TherapeuticsINDUSTRY | 1 | Dec 6, 2022 | clinicaltrials |
| NCT04450901 | Dose Escalation/Dose Expansion Study of YBL-006 in Patients With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 90 | Y Biologics Inc.INDUSTRY | 3 | Dec 5, 2022 | clinicaltrials |
| NCT02643303 | A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers | completed | Phase 1 / Phase 2 | 58 | Ludwig Institute for Cancer ResearchOTHER | 1 | Dec 2, 2022 | clinicaltrials |
| NCT05338957 | A Study of MRG002 in the Treatment of Patients With HER2-expressed Advanced Malignant Solid Tumors. | unknown | Phase 1 / Phase 2 | 30 | Shanghai Miracogen Inc.INDUSTRY | 1 | Dec 1, 2022 | clinicaltrials |
| NCT03980041 | Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275) | completed | Phase 2 | 49 | Infinity Pharmaceuticals, Inc.INDUSTRY | 7 | Nov 25, 2022 | clinicaltrials |
| NCT05602792 | A Study of T3011 Administered Via Intratumoral Injection in Patients With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 233 | ImmVira Pharma Co. LtdINDUSTRY | 1 | Nov 2, 2022 | clinicaltrials |
| NCT05598268 | A Study of T3011 Administered Via Intravenously in Patients With Advanced Solid Tumors. | unknown | Phase 1 / Phase 2 | 74 | ImmVira Pharma Co. LtdINDUSTRY | 1 | Oct 28, 2022 | clinicaltrials |
| NCT02593786 | A Study of Safety, Tolerability and Pharmacokinetics of Nivolumab in Chinese Subjects With Previously Treated Advanced or Recurrent Solid Tumors(CheckMate 077) | completed | Phase 1 / Phase 2 | 58 | Bristol-Myers SquibbINDUSTRY | 1 | Oct 24, 2022 | clinicaltrials |
| NCT04172454 | Safety and Efficacy of AK104, a PD-1/CTLA-4 Bispecific Antibody, in Selected Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 68 | AkesoINDUSTRY | 1 | Oct 12, 2022 | clinicaltrials |
| NCT02910726 | A Study Comparing Green Fluorescent Dye and Radioactive Dye for Sentinel Lymph Node Biopsy in Pediatric Cancers | completed | Phase 2 / Phase 3 | 6 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Oct 5, 2022 | clinicaltrials |
| NCT04765462 | Allogeneic γδ T Cell Therapy for the Treatment of Solid Tumors | unknown | Phase 1 / Phase 2 | 60 | Chinese PLA General HospitalOTHER | 1 | Oct 4, 2022 | clinicaltrials |
| NCT05457517 | A Phase 1b/2 Study of YL-13027 Combined With Sintilimab in Patients With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 49 | Shanghai YingLi Pharmaceutical Co. Ltd.INDUSTRY | 1 | Sep 27, 2022 | clinicaltrials |
| NCT03085914 | A Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Participants With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723) | completed | Phase 1 / Phase 2 | 70 | Incyte CorporationINDUSTRY | 1 | Sep 23, 2022 | clinicaltrials |
| NCT03965845 | A Study of Telaglenastat (CB-839) in Combination With Palbociclib in Patients With Solid Tumors | completed | Phase 1 / Phase 2 | 53 | Calithera Biosciences, IncINDUSTRY | 1 | Sep 19, 2022 | clinicaltrials |
| NCT02639546 | Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors(iMATRIXcobi) | completed | Phase 1 / Phase 2 | 56 | Hoffmann-La RocheINDUSTRY | 7 | Sep 16, 2022 | clinicaltrials |
Data updated 23 days agoSource updated Apr 12, 2023source: clinicaltrials